Home > Boards > US Listed > Medical - Drugs > Dr. Reddy's Laboratories Limited (RDY)

Dr. Reddy's Announces the Completion of Two Acquisitions

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
buhg1b Member Profile
 
Followed By 8
Posts 737
Boards Moderated 0
Alias Born 05/03/07
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 9:01:20 AM
Dr. Reddy’s Partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a Potential Treatment of COVID-19 Business Wire - 7/1/2020 4:10:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/29/2020 7:26:11 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/25/2020 3:05:33 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/23/2020 2:05:50 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/19/2020 10:09:58 AM
Dr. Reddy's Laboratories announces the launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market Business Wire - 6/19/2020 5:39:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/16/2020 8:05:04 AM
Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F Business Wire - 6/16/2020 1:48:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/15/2020 8:21:09 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/15/2020 7:53:42 AM
Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir Business Wire - 6/13/2020 5:15:00 AM
Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market Business Wire - 6/12/2020 7:44:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 8:23:55 AM
Dr. Reddy’s Laboratories Completes the Acquisition of Select Business Divisions of Wockhardt Business Wire - 6/10/2020 5:49:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 7:47:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/28/2020 7:17:59 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/22/2020 9:10:34 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 7:14:33 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 6:29:32 AM
Dr. Reddy’s Q4 & FY20 Financial Results Business Wire - 5/20/2020 6:45:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/18/2020 7:35:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2020 6:36:24 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2020 9:54:27 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2020 9:41:55 AM
buhg1b   Friday, 05/02/08 09:22:11 AM
Re: None
Post # of 18 
Dr. Reddy's Announces the Completion of Two Acquisitions
Thursday May 1, 7:23 am ET

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE:RDY - News) announced that it has completed two acquisitions: The Dow Chemical Company’s Dowpharma Small Molecules Business associated with its Mirfield and Cambridge, UK sites and BASF’s pharmaceutical contract manufacturing business and related facility in Shreveport, Louisiana, USA. Further financial terms and conditions of the transaction are not being disclosed.

The acquisition of The Dow Chemical Company’s Dowpharma Small Molecules Business associated with the 2 UK sites includes the relevant business, customer contracts, associated products, process technology, intellectual property, and trademarks as well as the transfer of the Mirfield and Cambridge facilities. Employees directly related to the business located at the Cambridge and Mirfield sites will become part of Dr Reddy’s. Dr. Reddy’s will also have a non-exclusive license to Dow’s Pfēnex Expression Technology™ for biocatalysis development.

The acquisition of BASF’s pharmaceutical contract manufacturing business and related facility includes the relevant business, customer contracts, related ANDAs and NDAs, trademarks, as well as the manufacturing facility and assets at Shreveport, Louisiana. It also includes a tolling and supply agreement. Employees directly related to the business located at Shreveport site will become part of Dr Reddy’s.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories was established in 1984 in Hyderabad, India, and is a global pharmaceutical company with proven research capabilities. Dr. Reddy’s conducts research in the areas of diabetes, obesity, cardiovascular diseases, anti-infectives and inflammation. The Indian based company produces finished dosage forms, active pharmaceutical ingredients and biotechnology products which are marketed globally, with focus on India, US, Europe and Russia. (www.drreddys.com)


Contact:

Dr. Reddy's Laboratories
Nikhil Shah, +91-40-66511532
(Investors and Financial Analysts)
nikhilshah@drreddys.com
Mythili Mamidanna, +91-40-66511620 (Media)
mythilim@drreddys.com

Source: Dr. Reddy's Laboratories


http://biz.yahoo.com/bw/080501/20080501005568.html?.v=1

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist